|
🐜
|
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
23 auth.
A. Shaw,
Dong-Wan Kim,
K. Nakagawa,
T. Seto,
L. Crinò,
M. Ahn,
T. D. De Pas,
B. Besse,
B. Solomon,
F. Blackhall,
...
Yi-long Wu,
Michael Thomas,
K. O'Byrne,
D. Moro-Sibilot,
D. Camidge,
T. Mok,
V. Hirsh,
Gregory Riely,
S. Iyer,
V. Tassell,
A. Polli,
K. Wilner,
P. Jänne
|
11 |
2013 |
11
🐜
|
|
🐜
|
Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC
20 auth.
M. Socinski,
R. Jotte,
F. Cappuzzo,
F. Orlandi,
D. Stroyakovskiy,
N. Nogami,
D. Rodríguez-Abreu,
D. Moro-Sibilot,
C. Thomas,
F. Barlesi,
...
G. Finley,
C. Kelsch,
Anthony Lee,
S. Coleman,
Yu Deng,
Yijing Shen,
M. Kowanetz,
A. López-Chávez,
A. Sandler,
M. Reck
|
11 |
2018 |
11
🐜
|
|
🐜
|
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
228 auth.
L. Paz-Ares,
M. Dvorkin,
Yuanbin Chen,
N. Reinmuth,
K. Hotta,
D. Trukhin,
G. Statsenko,
M. Hochmair,
M. Özgüroğlu,
J. Ji,
O. Voitko,
A. Poltoratskiy,
Santiago Ponce,
F. Verderame,
L. Havel,
...
I. Bondarenko,
A. Każarnowicz,
G. Losonczy,
N. Conev,
J. Armstrong,
N. Byrne,
N. Shire,
Haiyi Jiang,
J. Goldman,
E. Batagelj,
Ignacio Casarini,
A. V. Pastor,
S. Sena,
J. Zarbá,
O. Burghuber,
S. Hartl,
B. Lamprecht,
M. Studnicka,
L. Schlittler,
Fabricio Augusto Martinelli de Oliveira,
A. Calabrich,
G. Girotto,
P. Reis,
Carlo Gorini,
Peo Rafael Martins De Marchi,
C. Baldotto,
C. Sette,
M. Zukin,
A. Dudov,
R. Ilieva,
K. Koynov,
R. Krasteva,
I. Tonev,
S. Valev,
V. Venkova,
M. Bi,
Chengshui Chen,
Yuan Chen,
Zhendong Chen,
J. Fang,
Jifeng Feng,
Zhigang Han,
Jie Hu,
Yi Hu,
Wei Li,
Zongan Liang,
Zhong Lin,
R. Ma,
Shenglin Ma,
K. Nan,
Y. Shu,
Kai Wang,
Mengzhao Wang,
Gang Wu,
N. Yang,
Zhi-Xiong Yang,
He-long Zhang,
Wei Zhang,
Jun Zhao,
Yanqiu Zhao,
Caicun Zhou,
Jianying Zhou,
Xiang-dong Zhou,
V. Kolek,
L. Koubková,
J. Roubec,
J. Skřičková,
M. Zemanova,
C. Chouaid,
W. Hilgers,
H. Léna,
D. Moro-Sibilot,
G. Robinet,
P. Souquet,
J. Alt,
H. Bischoff,
C. Grohé,
E. Laack,
S. Lang,
J. Panse,
C. Schulz,
K. Bogos,
E. Csánky,
Anea Fülöp,
Z. Horváth,
Judit Kósa,
I. Laczó,
G. Pajkos,
Z. Pápai,
Zsolt Pápai Székely,
V. Sárosi,
A. Somfay,
É. Ezer,
Anás Telekes,
J. Bar,
M. Gottfried,
N. Heching,
Alona Zer Kuch,
R. Bartolucci,
A. Bettini,
A. Delmonte,
M. Garassino,
M. Minelli,
F. Roila,
S. Atagi,
K. Azuma,
H. Goto,
K. Goto,
Yu Hara,
H. Hayashi,
T. Hida,
Kenya Kanazawa,
S. Kanda,
Y. H. Kim,
S. Kuyama,
T. Maeda,
M. Morise,
Y. Nakahara,
M. Nishio,
N. Nogami,
I. Okamoto,
H. Saito,
M. Shinoda,
S. Umemura,
T. Yoshida,
N. Claessens,
R. Cornelissen,
Lizza Heniks,
Jeroen Hiltermann,
E. Smit,
A. J. S. D. Brekel,
D. Kowalski,
S. Mańdziuk,
Robert Mróz,
M. Wojtukiewicz,
T. Ciuleanu,
D. Ganea,
A. Ungureanu,
A. Luft,
V. Moiseenko,
D. Sakaeva,
A. Smolin,
Alexander Vasilyev,
L. Vladimirova,
Igor Anasina,
J. Chovanec,
P. Demo,
R. Godal,
P. Kasan,
M. Stresko,
M. Urda,
E. Cho,
Joo‐Hang Kim,
Sang-We Kim,
Gyeong-Won Lee,
Jong-Seok Lee,
K. Lee,
K. Lee,
Yun-Gyoo Lee,
M. Molla,
M. D. Gómez,
J. I. D. Mingorance,
D. Casado,
M. L. Brea,
M. M. Tarruella,
T. M. Bueno,
A. N. Mendivil,
Luis Paz-Ares Rodríguez,
S. P. Aix,
M. Campelo,
G. Chang,
Yen-Hsun Chen,
C. Chiu,
T. Hsia,
Kang-Yun Lee,
Chien-Te Li,
Chin-Chou Wang,
Yu-Feng Wei,
Shang‐Yin Wu,
A. Alacacıoğlu,
I. Çiçin,
A. Demirkazık,
M. Erman,
T. Göksel,
H. Adamchuk,
O. Kolesnik,
A. Kryzhanivska,
Y. Ostapenko,
S. Shevnia,
Y. Shparyk,
G. Ursol,
N. Voitko,
I. Vynnychenko,
S. Babu,
A. Chiang,
W. Chua,
S. Dakhil,
A. Dowlati,
Basir Haque,
Rodney Jamil,
J. Knoble,
Shailena Lakhanpal,
Kailhong Mi,
P. Nikolinakos,
S. Powell,
H. Ross,
E. Schaefer,
J. Schneider,
Joseph E. Spahr,
D. Spigel,
J. Stilwill,
C. Sumey,
Michael Williamson
|
10 |
2019 |
10
🐜
|
|
🐜
|
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
22 auth.
J. Soria,
D. Tan,
R. Chiari,
Yi-long Wu,
L. Paz-Ares,
J. Wolf,
Sarayut Lucien Geater,
S. Orlov,
D. Cortinovis,
Chong-Jen Yu,
...
M. Hochmair,
A. Cortot,
C. Tsai,
D. Moro-Sibilot,
R. Campelo,
T. McCulloch,
P. Sen,
M. Dugan,
Serafino Pantano,
F. Branle,
C. Massacesi,
G. Castro
|
9 |
2017 |
9
🐜
|
|
🐜
|
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
21 auth.
G. Zalcman,
J. Mazières,
J. Margery,
L. Greillier,
C. Audigier-Valette,
D. Moro-Sibilot,
O. Molinier,
R. Corre,
I. Monnet,
V. Gounant,
...
F. Rivière,
H. Janicot,
R. Gervais,
C. Locher,
B. Milleron,
Q. Tran,
M. Lebitasy,
F. Morin,
C. Créveuil,
J. Parienti,
A. Scherpereel
|
9 |
2016 |
9
🐜
|
|
🐜
|
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
20 auth.
M. Reck,
T. Mok,
M. Nishio,
R. Jotte,
F. Cappuzzo,
F. Orlandi,
D. Stroyakovskiy,
N. Nogami,
D. Rodríguez-Abreu,
D. Moro-Sibilot,
...
C. Thomas,
F. Barlesi,
G. Finley,
Anthony Lee,
S. Coleman,
Yu Deng,
M. Kowanetz,
G. Shankar,
W. Lin,
M. Socinski
|
9 |
2019 |
9
🐜
|
|
🐜
|
Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer.
27 auth.
A. Depierre,
B. Milleron,
D. Moro-Sibilot,
S. Chevret,
E. Quoix,
B. Lebeau,
D. Braun,
J. Breton,
E. Lemarié,
S. Gouva,
N. Paillot,
J. Bréchot,
H. Janicot,
F. Lebas,
P. Terrioux,
...
J. Clavier,
P. Foucher,
M. Monchâtre,
D. Coëtmeur,
M. Level,
P. Leclerc,
F. Blanchon,
J. Rodier,
L. Thiberville,
A. Villeneuve,
V. Westeel,
C. Chastang
|
9 |
2002 |
9
🐜
|
|
🐜
|
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
19 auth.
J. Mazières,
S. Peters,
B. Lepage,
A. Cortot,
F. Barlesi,
M. Beau-Faller,
B. Besse,
H. Blons,
A. Mansuet-Lupo,
T. Urban,
...
D. Moro-Sibilot,
É. Dansin,
C. Chouaid,
M. Wislez,
J. Diebold,
E. Felip,
I. Rouquette,
J. Milia,
O. Gautschi
|
9 |
2013 |
9
🐜
|
|
🐜
|
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
18 auth.
S. Ou,
J. Ahn,
L. de Petris,
R. Govindan,
J. Yang,
B. Hughes,
H. Léna,
D. Moro-Sibilot,
A. Bearz,
Santiago Viteri Ramírez,
...
T. Mekhail,
A. Spira,
W. Bordogna,
B. Balas,
P. N. Morcos,
Annabelle Monnet,
A. Zeaiter,
Dong-Wan Kim
|
9 |
2016 |
9
🐜
|
|
🐜
|
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
23 auth.
E. Quoix,
G. Zalcman,
J. Oster,
V. Westeel,
E. Pichon,
A. Lavolé,
J. Dauba,
D. Debieuvre,
P. Souquet,
L. Bigay-Gamé,
...
É. Dansin,
M. Poudenx,
O. Molinier,
F. Vaylet,
D. Moro-Sibilot,
D. Herman,
J. Bennouna,
J. Trédaniel,
A. Ducoloné,
M. Lebitasy,
L. Baudrin,
S. Laporte,
B. Milleron
|
9 |
2011 |
9
🐜
|
|
🐜
|
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
49 auth.
M. Garassino,
J. Whisenant,
Li-Ching Huang,
A. Trama,
V. Torri,
F. Agustoni,
J. Baena,
G. Banna,
R. Berardi,
A. Bettini,
E. Bria,
M. Brighenti,
J. Cadranel,
A. De Toma,
C. Chini,
...
A. Cortellini,
E. Felip,
G. Finocchiaro,
P. Garrido,
C. Genova,
R. Giusti,
V. Gregorc,
F. Grossi,
F. Grosso,
S. Intagliata,
N. La Verde,
Stephen V. Liu,
J. Mazières,
E. Mercadante,
O. Michielin,
G. Minuti,
D. Moro-Sibilot,
G. Pasello,
A. Passaro,
V. Scotti,
P. Solli,
E. Stroppa,
M. Tiseo,
G. Viscardi,
L. Voltolini,
Yi-long Wu,
S. Zai,
V. Pancaldi,
A. Dingemans,
J. V. van Meerbeeck,
F. Barlesi,
H. Wakelee,
S. Peters,
L. Horn
|
8 |
2020 |
8
🐜
|
|
🐜
|
Ectopic Activation of Germline and Placental Genes Identifies Aggressive Metastasis-Prone Lung Cancers
17 auth.
S. Rousseaux,
A. Debernardi,
Baptiste Jacquiau,
Anne-Laure Vitte,
A. Vésin,
H. Nagy-Mignotte,
D. Moro-Sibilot,
P. Brichon,
S. Lantuejoul,
P. Hainaut,
...
J. Laffaire,
A. de Reyniès,
D. Beer,
J. Timsit,
C. Brambilla,
E. Brambilla,
S. Khochbin
|
8 |
2013 |
8
🐜
|
|
🐜
|
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
20 auth.
K. Nakagawa,
E. Garon,
T. Seto,
M. Nishio,
S. Ponce Aix,
L. Paz-Ares,
C. Chiu,
Keunchil Park,
S. Novello,
E. Nadal,
...
F. Imamura,
K. Yoh,
J. Shih,
K. Au,
D. Moro-Sibilot,
S. Enatsu,
A. Zimmermann,
B. Frimodt-Moller,
C. Visseren-Grul,
M. Reck
|
8 |
2019 |
8
🐜
|
